Biomerica, Inc. (NASDAQ:BMRA – Get Free Report) passed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $2.15 and traded as low as $1.5833. Biomerica shares last traded at $1.60, with a volume of 2,401 shares trading hands.
Wall Street Analysts Forecast Growth
A number of equities analysts have issued reports on the stock. Citizens Jmp began coverage on shares of Biomerica in a research report on Tuesday, May 5th. They set a “mkt outperform” rating and a $9.00 target price for the company. Weiss Ratings lowered shares of Biomerica from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, June 5th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has a consensus rating of “Sell” and an average price target of $9.00.
Check Out Our Latest Stock Report on BMRA
Biomerica Trading Up 1.9%
Institutional Trading of Biomerica
An institutional investor recently raised its position in Biomerica stock. DRW Securities LLC lifted its holdings in shares of Biomerica, Inc. (NASDAQ:BMRA – Free Report) by 62.9% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 16,925 shares of the company’s stock after buying an additional 6,533 shares during the period. DRW Securities LLC owned 0.56% of Biomerica worth $43,000 at the end of the most recent reporting period. Institutional investors own 22.28% of the company’s stock.
Biomerica Company Profile
Biomerica, Inc is a developer, manufacturer and marketer of in vitro diagnostic tests for clinical diagnostic, life science research and food safety applications. The company’s product portfolio includes enzyme-linked immunosorbent assays (ELISAs), lateral flow immunoassays, point-of-care devices and specialty reagents designed to aid in the detection and monitoring of gastrointestinal, metabolic and autoimmune conditions. Biomerica’s diagnostics are used by hospitals, clinical and reference laboratories, and research institutions seeking solutions for early disease detection and patient management.
Key offerings from Biomerica include serological tests for celiac disease and gluten intolerance, quantitative assays for colorectal cancer screening markers such as M2-PK, and a range of point-of-care kits for metabolic monitoring.
Read More
- Five stocks we like better than Biomerica
- Premium Retail’s Stress Test Is Separating Winners From Losers
- D-Wave Quantum or a Quantum ETF: Which Is the Better Bet?
- GE Vernova Just Sent a Mixed AI Signal to Investors
- Alphabet Crushed Earnings, But One Number Spooked the Market
Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with MarketBeat.com's FREE daily email newsletter.
